CTMX vs JNJ · rev $11.7M vs P/E 17, rev $49.37B
CytomX Therapeutics Inc (CTMX) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported CTMX revenue for 2026-06-30 was $11.7M. Net income was -$38.9M. Revenue was up 13.8% from 2026-03-31 to 2026-06-30. CTMX currently screens at market cap $653.1M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
CTMX currently screens at market cap $653.1M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the CTMX and JNJ stock pages for the full models.
Not investment advice.